Connect with us

Headlines

Eye Health Firm Acquired in $800M Deal

The acquisition focuses on treatments for inherited retinal disorders.

mm

Published

on

CAMBRIDGE, MA — Biogen announced that it has completed its acquisition of Nightstar Therapeutics, a clinical-stage gene therapy company focused on treatments for inherited retinal disorders.

As a result of the acquisition, Biogen now has added two mid- to late-stage clinical assets, as well as preclinical programs, in ophthalmology, according to a press release.

The transaction value was about $800 million. Nightstar’s common stock will no longer be listed for trading on the Nasdaq Global Select Market.

Nightstar is developing adeno-associated virus treatment. Its lead asset is NSR-REP1 for the treatment of choroideremia, a rare degenerative, X-linked inherited retinal disorder that leads to blindness and has no approved treatments. Initially, patients with choroideremia experience poor night vision, and over time progressive visual loss leads to complete blindness.

NSR-RPGR is Nightstar’s second clinical program for the treatment of X-linked retinitis pigmentosa, which is also a rare inherited retinal disease primarily affecting males with no approved treatments. The disease leads to loss of photoreceptor cells, resulting in retinal dysfunction by adolescence and early adulthood, progressing to legal blindness when patients reach their 40s.

“Today marks a significant achievement for Biogen,” said Michel Vounatsos, Biogen’s CEO. “The acquisition of Nightstar further bolsters our pipeline and is an important step forward toward our goal of a multi-franchise portfolio across complementary modalities. We look forward to working now as one Biogen team with the goal of bringing breakthrough therapies to patients to slow or halt blindness across a range of inherited retinal diseases.”

Advertisement

Since launching in 2014, INVISION has won 23 international journalism awards for its publication and website. Contact INVISION's editors at [email protected].

SPONSORED VIDEO

Sponsored by Shamir

Customer Focused, Service Oriented, Forward Thinking

Shamir is the recognized world leader in custom-designed technology for life improvement, fashion, performance sports, occupational single vision, and progressive lenses. Our values, the driving force behind our ideas and actions, keep the ECP in the center. Every Shamir representative is personally committed to our customers’ vision, and to providing the best service and support to meet and exceed their expectations, all with a personal touch.

Click here for more information.

Promoted Headlines

Advertisement

Advertisement

Subscribe

INVISIONMAG.COM
BULLETINS

Get the most important news and business ideas for eyecare professionals every weekday from INVISION.

Advertisement

Most Popular